UNCY

NASDAQ · Biotechnology

Unicycive Therapeutics Inc

Penny Stocks Biotech Stocks Healthcare Stocks

$4.69

-3.01 (-39.09%)

UNCY News2 articles

Unicycive Therapeutics Plunges After FDA Issues Second CRL on Kidney Drug

Unicycive Therapeutics shares plunged nearly 48% in premarket trading Tuesday after the FDA issued a second complete response letter for its kidney disease drug, oxylanthanum carbonate, due to third-party manufacturing issues.

Markets yesterday

FDA Decisions Loom for ACHV and UNCY Amid Manufacturing Hurdles

ACHV dropped 9.5% as its FDA deadline passed with a manufacturing-related rejection expected; UNCY fell 2.8% ahead of a June 29 decision. Both stocks face third-party manufacturing issues.